Premium
Anticancer drug distribution in lymph and blood during adjuvant chemotherapy after surgery for gastric carcinoma. A study with a combined preparation of 1‐(2‐tetrahydrofuryl)‐5‐fluorouracil and uracil
Author(s) -
Hanaue Hitoshi,
Kurosawa Tsutomu,
Kitano Yoshiaki,
Miyakawa Sadaaki,
Nemoto Akihisa,
Yamamoto Hiroshi,
Asagoe Tatsuo,
Takada Tadahiro,
Yasuda Hideki,
Shikata JunIchi
Publication year - 1987
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19870501)59:9<1571::aid-cncr2820590907>3.0.co;2-9
Subject(s) - tegafur , medicine , uracil , lymph , fluorouracil , gastric carcinoma , chemotherapy , carcinoma , gastroenterology , cancer , pharmacology , pathology , chemistry , biochemistry , dna
Previously the authors reported that the fat emulsion of 1‐(2‐tetrahydrofuryl)‐5‐fluorouracil, tegafur (FT‐207), yielded significantly higher concentrations of tegafur in the lymph and plasma compared to tegafur enteric‐coated granules (FT‐G). However, the emulsification did not improve the metabolic conversion rate of tegafur to 5‐fluorouracil (5‐FU). A study was performed to assay the plasma and lymphatic concentrations of tegafur, 5‐FU, and uracil in seven patients after radical surgery for gastric carcinoma who were given a combined oral preparation of FT‐207 and uracil (UFT). Both lymph and plasma 5‐FU levels after UFT were 20 times greater than those after FT‐G, although FT‐207 levels were not different. Patients given UFT showed significantly greater 5‐FU and uracil concentrations in the lymph compared with the plasma. The results of this study suggest a potential use of UFT as an adjuvant postoperative chemotherapeutic agent for gastric carcinoma.